《全球慢性阻塞性肺疾病创议》2026关键更新要点解读

doi:10.19983/j.issn.2096-8493.20250209

结核与肺部疾病杂志 ›› 2026, Vol. 7 ›› Issue (2): 152-155.doi: 10.19983/j.issn.2096-8493.20250209

• 标准解读 • 上一篇

《全球慢性阻塞性肺疾病创议》2026关键更新要点解读

刘懿典¹, 袁雪芳², 龙颖姣¹^,³^,⁴^,⁵()

¹ 中南大学湘雅二医院呼吸与危重症医学科, 长沙 410011
² 湖南旺旺医院呼吸内科, 长沙 410009
³ 中南大学呼吸疾病研究所, 长沙 410011
⁴ 湖南省呼吸与危重症疾病临床医学研究中心, 长沙 410011
⁵ 中南大学呼吸疾病诊疗中心, 长沙 410011

收稿日期:2025-12-25 出版日期:2026-04-20 发布日期:2026-04-13
通信作者: 龙颖姣 E-mail:longyingjiao@163.com
基金资助:
湖南省自然科学基金(2024JJ5487);癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(2025ZD0548800);国家临床重点专科建设项目(Z2023164)

Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report

Liu Yidian¹, Yuan Xuefang², Long Yingjiao¹^,³^,⁴^,⁵()

¹ Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha 410011, China
² Department of Respiratory Medicine, Hunan Want Want Hospital, Changsha 410009, China
³ Research Unit of Respiratory Disease, Central South University, Changsha 410011, China
⁴ Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha 410011, China
⁵ Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha 410011, China

Received:2025-12-25 Online:2026-04-20 Published:2026-04-13
Contact: Long Yingjiao E-mail:longyingjiao@163.com
Supported by:
Natural Science Foundation of Hunan Province(2024JJ5487);National Major Scientific and Technological Special Project for Cancer, Cardiovascular and Cerebrovascular, Respiratory, and Metabolic Disease Prevention and Treatment Research(2025ZD0548800);National Key Clinical Specialty Construction Projects of China(Z2023164)

摘要/Abstract

摘要：

慢性阻塞性肺疾病(简称“慢阻肺病”)是一种常见的可预防、可治疗的慢性气道疾病,《全球慢性阻塞性肺疾病创议》2026(Global Initiative for Chronic Obstructive Lung Disease 2026,GOLD 2026)的更新围绕早期筛查、动态精准评估,更契合临床实践,并首设人工智能赋能专章,对实现慢阻肺病全生命周期管理提供了指导。笔者现对GOLD 2026的重要更新内容作一解读,旨在更好地理解指南修订的方向和依据,以指导临床实践和未来研究方向。

关键词: 肺疾病,慢性阻塞性, 评论, 治疗, 规范, 评论

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable chronic airway disease. The updated Global Initiative for Chronic Obstructive Lung Disease 2026 (GOLD 2026) focuses on early screening and dynamic precise assessment, aligning more closely with clinical practice. For the first time, it includes a dedicated chapter on artificial intelligence empowerment, providing guidance for the implementation of whole-life-cycle management of COPD. The author herein reviews the key updates in GOLD 2026, aiming to facilitate a better understanding of the rationale and direction behind the guideline revisions, thereby informing clinical practice and future research directions.

Key words: Chronic obstructive pulmonary disease, Review, Treatment, Benchmarking, Comment

中图分类号:

R563.9

刘懿典, 袁雪芳, 龙颖姣. 《全球慢性阻塞性肺疾病创议》2026关键更新要点解读[J]. 结核与肺部疾病杂志, 2026, 7(2): 152-155. doi: 10.19983/j.issn.2096-8493.20250209

Liu Yidian, Yuan Xuefang, Long Yingjiao. Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report[J]. Journal of Tuberculosis and Lung Disease, 2026, 7(2): 152-155. doi: 10.19983/j.issn.2096-8493.20250209

参考文献 16

[1]	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi:10.1016/S0140-6736(18)30841-9. pmid: 29650248
[2]	Tisi S, Dickson JL, Horst C, et al. Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry. Eur Respir J, 2022, 60(6):2200795. doi:10.1183/13993003.00795-2022.
[3]	Bradley C, Boland A, Clarke L, et al. Diagnosis and treatment outcomes from prebronchodilator spirometry performed alongside lung cancer screening in a Lung Health Check programme. Thorax, 2023, 78(6):543-550. doi:10.1136/thorax-2022-219683.
[4]	Liu M, Yin D, Wang Y, et al. Comparing the Performance of Two Screening Questionnaires for Chronic Obstructive Pulmonary Disease in the Chinese General Population. Int J Chron Obstruct Pulmon Dis, 2023, 18:541-552. doi:10.2147/COPD.S403603.
[5]	Yang T, Cai B, Cao B, et al. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Ther Adv Respir Dis, 2023, 17: 17534666231167353. doi:10.1177/17534666231167353.
[6]	Whittaker H, Rubino A, Müllerová H, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 2022, 17:427-437. doi:10.2147/COPD.S346591.
[7]	Rhodes K, Patel D, Duong ML, et al. Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS/AVOIDEX programme. BMJ Open, 2025, 15(7):e097006. doi:10.1136/bmjopen-2024-097006.
[8]	Cazzola M, Matera MG. Clinically important deterioration: a composite tool for managing patients with COPD. Respir Med, 2022, 205:107054. doi:10.1016/j.rmed.2022.107054.
[9]	Newsome SD, Binns C, Kaunzner UW, et al. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]. Neurol Ther, 2023, 12(6):1909-1935. doi:10.1007/s40120-023-00549-7. pmid: 37819598
[10]	Deighton C, Rudolf M. How does rheumatoid arthritis need to be managed?. Clin Med (Lond), 2010, 10(2):151-153. doi:10.7861/clinmedicine.10-2-151.
[11]	Çolak Y, Afzal S, Marott JL, et al. Type-2 inflammation and lung function decline in chronic airway disease in the general population. Thorax, 2024, 79(4):349-358. doi:10.1136/thorax-2023-220972. pmid: 38195642
[12]	Ritchie AI, Donaldson GC, Hoffman EA, et al. Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry. Am J Respir Crit Care Med, 2024, 209(10):1208-1218. doi:10.1164/rccm.202307-1203OC.
[13]	Topole E, Biondaro S, Montagna I, et al. Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trials. ERJ Open Res, 2023, 9(1):00292-2022. doi:10.1183/23120541.00292-2022.
[14]	Wu Y, Xia S, Liang Z, et al. Artificial intelligence in COPD CT images: identification, staging, and quantitation. Respir Res, 2024, 25(1):319. doi:10.1186/s12931-024-02913-z.
[15]	Hasenstab KA, Yuan N, Retson T, et al. Automated CT staging of chronic obstructive pulmonary disease severity for predicting disease progression and mortality with a deep learning convolutional neural network. Radiol Cardiothorac Imaging, 2021, 3(2):e200477. doi:10.1148/ryct.2021200477.
[16]	Wu R, de Lara E, Liaqat D, et al. Feasibility of a wearable self-management application for patients with COPD at home: a pilot study. BMC Med Inform Decis Mak, 2024, 24(1):66. doi:10.1186/s12911-024-02461-y.

《全球慢性阻塞性肺疾病创议》2026关键更新要点解读

Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国防痨协会药学专业分会. 抗结核药治疗药物监测临床应用专家共识(2025年更新版)[J]. 结核与肺部疾病杂志, 2026, 7(2): 131-151.
[2]	李凯迪, 樊庆达, 姜文升. 含微乳头成分的IA期肺腺癌研究进展[J]. 结核与肺部疾病杂志, 2026, 7(1): 106-111.
[3]	张英奎, 张关霞, 杨自娟, 王秀川. 维持性血液透析患者合并颈部淋巴结结核一例并文献复习[J]. 结核与肺部疾病杂志, 2026, 7(1): 80-85.
[4]	郭芊, 郭菁. 行介入治疗肺癌患者中优质护理的应用及对患者生存质量影响的观察[J]. 结核与肺部疾病杂志, 2025, 6(S1): 82-83.
[5]	深圳市第三人民医院(国家感染性疾病临床医学研究中心), 中国防痨协会结核病与糖尿病专业分会, 中国防痨协会多学科诊疗专业分会. 结核病共病治疗中利福霉素类药物合理应用专家共识[J]. 结核与肺部疾病杂志, 2025, 6(6): 634-658.
[6]	田晓梅, 何小雪, 雷娟, 王晓炜, 古建军. 2019—2023年宁夏回族自治区病原学阳性肺结核治疗效果及影响因素分析[J]. 结核与肺部疾病杂志, 2025, 6(6): 703-709.
[7]	沙小兰, 田晓福, 田晓梅, 刘涛, 雷娟. 2018—2022年宁夏回族自治区耐多药/利福平耐药肺结核患者治疗转归及其影响因素分析[J]. 结核与肺部疾病杂志, 2025, 6(6): 710-716.
[8]	廖文平, 张理翌, 张文, 苏倩. 2020—2023年重庆市学生肺结核患者治疗转归及影响因素分析[J]. 结核与肺部疾病杂志, 2025, 6(6): 725-730.
[9]	苏伟, 刘胤杉, 罗旭善, 古丽孜拜尔·赛麦尔, 吐尔洪·吾守尔, 帕尔哈提·沙拉衣丁, 戚海波, 亚森·吐尔逊, 古丽米热·依明, 麦维兰江·阿不力米提, 周临军, 黄飞. 80例耐多药/利福平耐药肺结核患者全口服标准化短程治疗疗效观察[J]. 结核与肺部疾病杂志, 2025, 6(6): 731-737.
[10]	中国中西医结合学会中华中医药学会中华医学会. 耐药肺结核中西医结合诊疗指南[J]. 结核与肺部疾病杂志, 2025, 6(5): 477-494.
[11]	中国防痨协会多学科诊疗分会, 深圳市第三人民医院(国家感染性疾病临床医学研究中心), 首都医科大学附属北京朝阳医院, 广东省肺癌研究所. 肺结核与肺癌共病诊疗专家共识[J]. 结核与肺部疾病杂志, 2025, 6(5): 495-515.
[12]	安源, 白云龙, 赵庆龙, 姜雪, 潘艳, 杨帆. 2018—2022年吉林省利福平耐药肺结核患者特征及治疗情况分析[J]. 结核与肺部疾病杂志, 2025, 6(5): 566-572.
[13]	侯文俊, 田飞飞, 张时雨, 张耀文, 豆亚美, 薛涵, 崔虹艳. 2022—2024年北京市大兴区肺结核合并糖尿病及高血压患者的流行特征及治疗转归情况[J]. 结核与肺部疾病杂志, 2025, 6(5): 579-586.
[14]	段鸿飞. 《世界卫生组织endTB方案治疗耐多药结核病指南》解读[J]. 结核与肺部疾病杂志, 2025, 6(4): 361-364.
[15]	蒋琦, 马义铭, 陈燕. 《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种[J]. 结核与肺部疾病杂志, 2025, 6(2): 125-127.